Gene Therapy Briefs

Abstract

Get full access to this article

View all access options for this article.

References

Biogen Idec and TIGET. Biogen Idec, Fondazione Telethon and Ospedale San Raffaele announce global collaboration to develop gene therapies for hemophilia, 2015. Available at www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2456&M=NewsV2&PID=61997 (accessed February 3, 2015).

Biogen Idec. Olivier Danos joins Biogen Idec as senior vice president, gene therapy, 2014. Available at www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2382&M=NewsV2&PID=61997 (accessed February 3, 2015).

Biogen Idec. Biogen Idec 2014 revenues increase 40% to $9.7 billion, 2015. Available at www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2459&M=NewsV2&PID=61997 (accessed February 3, 2015).

Spark Therapeutics. Spark Therapeutics announces closing of its initial public offering, 2015. Available at www.sparktx.com/sites/default/files/fields/press-release/spark_-_closing_press_release_final_020415.pdf (accessed February 4, 2015).

Spark Therapeutics. Spark Therapeutics announces gene therapy collaboration in hemophilia B with Pfizer Inc, 2014. Available at www.sparktx.com/sites/default/files/fields/press-release/spark-pfizer_partnership_release_final_12.5.14v2_0.pdf (accessed February 4, 2015).

Pfizer. Pfizer expands rare disease research with establishment of gene therapy platform, 2014. Available at www.pfizer.com/news/press-release/press-release-detail/pfizer_expands_rare_disease_research_with_establishment_of_gene_therapy_platform (accessed February 4, 2015).

Treeway and uniQure. Treeway announces license and collaboration agreement with uniQure to develop a gene therapy for amyotrophic lateral sclerosis (ALS), 2015. Available at www.treeway.nl/treeway-and-uniqure-license-collaboration-agreement (accessed February 12, 2015).

Berger

and Hirschler

. Exclusive: First gene therapy drug sets million-euro price record. Reuters, Nov. 26, 2014. Available at www.reuters.com/article/2014/11/26/us-health-genetherapy-price-idUSKCN0JA1TP20141126 (accessed February 11, 2015).

Audentes Therapeutics. Audentes Therapeutics raises $42.5 million in series B financing, 2014. Available at http://audentestx.com/content/news/releases/120214.htm (accessed February 4, 2015).

10.

REGENXBIO. REGENXBIO raises $30 million in series C financing, 2015. Available at www.regenxbio.com/pages/news/documents/REGENXBIOSeriesCFinancing.pdf (accessed February 4, 2015).

11.

Juno Therapeutics. Juno Therapeutics establishes manufacturing presence in Washington State, 2015. Available at http://ir.junotherapeutics.com/phoenix.zhtml?c=253828&p=irol-newsArticle&ID=2014731 (accessed February 11, 2015).

12.

Bellicum Pharmaceuticals. Bellicum Pharmaceuticals announces closing of initial public offering and exercise of the underwriters' option, 2014. Available at http://ir.bellicum.com/phoenix.zhtml?c=253830&p=irol-newsArticle&ID=2001917 (accessed February 11, 2015).

13.

Novartis. Novartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technology, 2015. Available at www.novartis.com/newsroom/media-releases/en/2015/1884844.shtml?hootPostID=93a47dae1142f67c92df2c1c34807075 (accessed February 4, 2015).

14.

Amgen and Kite Pharma. Amgen and Kite Pharma announce strategic cancer immunotherapy collaboration to advance the application of novel chimeric antigen receptor (CAR) T cell therapies, 2015. Available at www.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=2002967 (accessed February 4, 2015).